Overall response rate, clinical benefit rate, and median progression-free survival by baseline characteristics
| . | n . | ORR, % (95% CI) . | CBR, % (95% CI) . | PFS, months (95% CI) . |
|---|---|---|---|---|
| Disease progressed | ||||
| On BTZ | 40 | 37.5 (22.7-54.2) | 55.0 (38.5-70.7) | 4.2 (2.6-5.8) |
| Within 60 d of BTZ | 15 | 26.7 (7.8-55.1) | 46.7 (21.3-73.4) | 7.6 (6.7-9.7) |
| BTZ in last prior line of therapy | ||||
| Yes | 27 | 25.9 (11.1-46.3) | 48.1 (28.7-68.1) | 4.9 (2.1-7.6) |
| No | 28 | 42.9 (24.5-62.8) | 57.1 (37.2-75.5) | 6.0 (3.9-7.6) |
| DEX in last BTZ-containing regimen | ||||
| Yes | 45 | 26.7 (14.6-41.9) | 46.7 (31.7-62.1) | 4.9 (2.6-6.7) |
| No | 10 | 70.0 (34.8-93.3) | 80.0 (44.4-97.5) | 6.2 (2.6-NR) |
| DEX in last prior line of therapy | ||||
| Yes | 37 | 32.4 (18.0-49.8) | 54.1 (36.9-70.5) | 4.2 (2.6-6.7) |
| No | 18 | 38.9 (17.3-64.3) | 50.0 (26.0-74.0) | 6.5 (2.6-9.7) |
| ISS Staging* | ||||
| Stage 1 | 18 | 61.1 (35.8-82.7) | 83.3 (58.6-96.4) | 6.9 (5.4-12.5) |
| Stage 2 | 23 | 21.7 (7.5-43.7) | 34.8 (16.4-57.3) | 3.0 (2.1-4.2) |
| Stage 3 | 13 | 15.4 (1.9-45.5) | 38.5 (13.9-68.4) | 4.9 (1.4-9.0) |
| . | n . | ORR, % (95% CI) . | CBR, % (95% CI) . | PFS, months (95% CI) . |
|---|---|---|---|---|
| Disease progressed | ||||
| On BTZ | 40 | 37.5 (22.7-54.2) | 55.0 (38.5-70.7) | 4.2 (2.6-5.8) |
| Within 60 d of BTZ | 15 | 26.7 (7.8-55.1) | 46.7 (21.3-73.4) | 7.6 (6.7-9.7) |
| BTZ in last prior line of therapy | ||||
| Yes | 27 | 25.9 (11.1-46.3) | 48.1 (28.7-68.1) | 4.9 (2.1-7.6) |
| No | 28 | 42.9 (24.5-62.8) | 57.1 (37.2-75.5) | 6.0 (3.9-7.6) |
| DEX in last BTZ-containing regimen | ||||
| Yes | 45 | 26.7 (14.6-41.9) | 46.7 (31.7-62.1) | 4.9 (2.6-6.7) |
| No | 10 | 70.0 (34.8-93.3) | 80.0 (44.4-97.5) | 6.2 (2.6-NR) |
| DEX in last prior line of therapy | ||||
| Yes | 37 | 32.4 (18.0-49.8) | 54.1 (36.9-70.5) | 4.2 (2.6-6.7) |
| No | 18 | 38.9 (17.3-64.3) | 50.0 (26.0-74.0) | 6.5 (2.6-9.7) |
| ISS Staging* | ||||
| Stage 1 | 18 | 61.1 (35.8-82.7) | 83.3 (58.6-96.4) | 6.9 (5.4-12.5) |
| Stage 2 | 23 | 21.7 (7.5-43.7) | 34.8 (16.4-57.3) | 3.0 (2.1-4.2) |
| Stage 3 | 13 | 15.4 (1.9-45.5) | 38.5 (13.9-68.4) | 4.9 (1.4-9.0) |
BTZ, bortezomib; CBR, clinical benefit rate; CI, confidence interval; DEX, dexamethasone; ISS, International Staging System; NR, not reached; ORR, overall response rate; PFS, progression-free survival.
One patient did not have baseline β2 microglobulin measurement.